1. Home
  2. BCDA vs HAO Comparison

BCDA vs HAO Comparison

Compare BCDA & HAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • HAO
  • Stock Information
  • Founded
  • BCDA N/A
  • HAO 2018
  • Country
  • BCDA United States
  • HAO China
  • Employees
  • BCDA N/A
  • HAO 30
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • HAO
  • Sector
  • BCDA Health Care
  • HAO
  • Exchange
  • BCDA Nasdaq
  • HAO NYSE
  • Market Cap
  • BCDA 7.9M
  • HAO 6.6M
  • IPO Year
  • BCDA N/A
  • HAO 2024
  • Fundamental
  • Price
  • BCDA $2.48
  • HAO $1.86
  • Analyst Decision
  • BCDA Strong Buy
  • HAO
  • Analyst Count
  • BCDA 1
  • HAO 0
  • Target Price
  • BCDA $25.00
  • HAO N/A
  • AVG Volume (30 Days)
  • BCDA 54.8K
  • HAO 7.0M
  • Earning Date
  • BCDA 03-26-2025
  • HAO 10-29-2024
  • Dividend Yield
  • BCDA N/A
  • HAO N/A
  • EPS Growth
  • BCDA N/A
  • HAO 20.20
  • EPS
  • BCDA N/A
  • HAO 0.04
  • Revenue
  • BCDA $71,000.00
  • HAO $48,519,836.00
  • Revenue This Year
  • BCDA N/A
  • HAO N/A
  • Revenue Next Year
  • BCDA N/A
  • HAO N/A
  • P/E Ratio
  • BCDA N/A
  • HAO $2.47
  • Revenue Growth
  • BCDA N/A
  • HAO 71.88
  • 52 Week Low
  • BCDA $1.63
  • HAO $0.09
  • 52 Week High
  • BCDA $8.85
  • HAO $10.60
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 49.50
  • HAO 59.38
  • Support Level
  • BCDA $2.12
  • HAO $1.75
  • Resistance Level
  • BCDA $2.73
  • HAO $2.02
  • Average True Range (ATR)
  • BCDA 0.23
  • HAO 0.39
  • MACD
  • BCDA 0.01
  • HAO -0.05
  • Stochastic Oscillator
  • BCDA 35.82
  • HAO 45.55

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About HAO HAOXI HEALTH TECHNOLOGY LTD

Haoxi Health Technology Ltd is an online marketing solution provider in China, with an advertiser client base mainly in the healthcare industry. Haoxi has been rooted in the field of local online effect marketing for many years, serving customers in various industries at home and abroad, and its main business is the medical industry. It generates its revenue by providing one-stop online marketing solutions, in particular online short video marketing solutions, to advertisers through its media partners. The company provides customized marketing solutions by planning, producing, placing, and optimizing online ads, especially online short video ads, to help its advertisers acquire, convert, and retain ultimate consumers on various online media platforms.

Share on Social Networks: